Compound library / Bone Health
Synthetic PTHrP(1-34) analogue, FDA-approved for postmenopausal osteoporosis with high fracture risk; explored in biohacking circles for bone remodeling. Acts preferentially on the anabolic arm of the PTH pathway.
| Category | Bone Health |
|---|---|
| Typical route | Subcutaneous |
| Half-life | ~1.7 hours |
| Common dose range | 80 mcg once daily (approved dose); research use mirrors this |
| Typical cycle length | Up to 18 months per FDA label; not recommended beyond 2 years cumulative anabolic therapy |
BioHack Track models Abaloparatide (Tymlos) at a half-life of 1.7 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Supplied as a pre-filled pen; no reconstitution needed.
Refrigerate until first use; pen stable at room temperature for up to 30 days after opening.
Prescription medication with a boxed warning for osteosarcoma risk (based on rat data — clinical significance unknown). Should be followed by an antiresorptive agent to preserve gained bone density.
Track Abaloparatide (Tymlos) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Abaloparatide (Tymlos) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.